OncLive® On Air
OncLive® On Air
In OncLive® On Air, you can expect to hear interviews with academic oncologists on the thought-provoking oncology presentations they give at the OncLive® State of the Science Summits. The topics in oncology vary, from systemic therapies, surgery, radiation therapy, to emerging therapeutic approaches in a particular type of cancer. This includes lung cancer, breast cancer, gastrointestinal cancers, hematologic malignancies, gynecologic cancers, genitourinary cancers, and more.
Episodes
Mentioned books
Dec 15, 2022 • 13min
S8 Ep6: FDA Approval Insights: Tremelimumab Plus Durvalumab and Chemotherapy in NSCLC
Dr Johnson discusses the FDA approval of tremelimumab plus durvalumab and chemotherapy in non–small cell lung cancer, key data from the POSEIDON trial, and the combination’s efficacy and tolerability in various patient populations.
Dec 12, 2022 • 16min
S8 Ep5: Acuna Discusses US Liver Cancer Incidence in Individuals of Mexican Descent
Nicholas Acuna discusses research showing that incidence of liver cancer increases over time in people of Mexican descent living in Los Angeles, the “Latino paradox” in health outcomes, and the next steps for this research.
Dec 8, 2022 • 13min
S8 Ep4: Brody Previews ASH 2022 Data With Pirtobrutinib, CAR T-cell Therapy, and Glofitamab in MCL
Dr Brody previews mantle cell lymphoma data being presented at the 2022 ASH Annual Meeting and Exposition, including promising data on pirtobrutinib from the BRUIN trial, the potential for CAR T-cell therapy as evidenced in the ZUMA-2 trial, and how immunotherapies such as glofitamab are expanding the treatment paradigm.
Dec 5, 2022 • 18min
S8 Ep3: FDA Approval Insights: Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer
Dr Matulonis discusses the FDA approval of mirvetuximab soravtansine-gynx in folate receptor alpha–positive, platinum-resistant ovarian cancer, key efficacy and safety data from the SORAYA trial, and how further research can continue the momentum behind finding effective ovarian cancer treatments.
Dec 1, 2022 • 15min
S8 Ep2: Leone Lays Out Research Needs and Treatment Approaches in Male Breast Cancer
Dr Leone discusses the distinguishing features of male breast cancer, the benefits and limitations of current treatments, and the importance of raising awareness about this breast cancer subset to propel further research.
Nov 28, 2022 • 14min
S8 Ep1: Florez Discusses Crucial Aspects of Cancer Care Equity and Survivorship
Dr Florez discusses why cancer care equity and survivorship should be a priority for all physicians, the steps the health care system needs to take to address disparities in these areas, and specific ways that Dana-Farber is working to close these gaps.
Nov 24, 2022 • 19min
S7 Ep50: FDA Approval Insights: Durvalumab Plus Tremelimumab in HCC
Dr Abou-Alfa discusses the FDA approval of durvalumab plus tremelimumab in unresectable hepatocellular carcinoma, the regimen’s unique mechanism of action, and the importance of expanding global access to this combination.
Nov 21, 2022 • 13min
S7 Ep49: Crane Helps Gynecologic Fellows Deliver Care in a Complicated Time
Dr Crane discusses why Atrium Health decided to launch a gyn onc fellowship, how she helps fellows navigate the current political landscape while maintaining high-level care, and how she tries to model a good work-life balance for her trainees.
Nov 17, 2022 • 22min
S7 Ep48: Oppong Sheds Light on Racial Disparities in Breast Cancer Diagnosis and Mortality
Dr Oppong discusses factors that contribute to the ongoing disparity in breast cancer deaths among Black women vs White women, the importance of increased access to high-quality screening, and the need for more inclusive research efforts to close the gaps in breast cancer diagnosis and care.
Nov 14, 2022 • 14min
S7 Ep47: FDA Approval Insights: Teclistamab in Relapsed/Refractory Multiple Myeloma
Dr Garfall discusses the FDA approval of teclistamab in relapsed/refractory multiple myeloma, key efficacy and safety data from the MajesTEC-1 trial, and the drug’s unique mechanism of action compared with other anti-myeloma agents.
